Doctor Antonio J Vallejo-Vaz
University of Seville, Seville (Spain)
Member of:
/f/125658/4843x1496/b9b684dbb2/eapc-acronym-name-rgb.png)
Atherothrombotic residual risk in coronary and peripheral artery disease patients on guideline-recommended antiplatelet monotherapy: baseline preliminary results from the RESRISK study
Event: ESC Congress 2021 - The Digital Experience
Topic: Secondary Prevention
Session: Risk Factors and Prevention ePosters
The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry: analyses from over 55,000 cases and 68 countries
Event: ESC Congress 2019
Topic: Lipids
Session: Late Breaking Science in Prevention 1
Predictive factors for alirocumab dose increase in patients with hypercholesterolaemia and high cardiovascular risk: from the ODYSSEY COMBO I and II trials
Event: ESC Congress 2017
Topic: Lipids (Epidemiology and Prevention)
Session: Lipids
Primary prevention of patients with high LDL-cholesterol levels greater than 4.9 mmol/l: analysis from the WOSCOPS trial
Event: ESC Congress 2016
Topic: Primary cardiovascular prevention: interventions and outcomes
Session: Clinical Trial Update Prevention
ESC 365 is supported by
